CA2446806A1 - Anti-cd26 monoclonal antibodies as therapy for diseases associated with cells expressing cd26 - Google Patents

Anti-cd26 monoclonal antibodies as therapy for diseases associated with cells expressing cd26 Download PDF

Info

Publication number
CA2446806A1
CA2446806A1 CA002446806A CA2446806A CA2446806A1 CA 2446806 A1 CA2446806 A1 CA 2446806A1 CA 002446806 A CA002446806 A CA 002446806A CA 2446806 A CA2446806 A CA 2446806A CA 2446806 A1 CA2446806 A1 CA 2446806A1
Authority
CA
Canada
Prior art keywords
cell
antibody
cancer
cells
antibodies
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002446806A
Other languages
English (en)
French (fr)
Inventor
Nam H. Dang
Chikao Morimoto
Stuart Schlossman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Dana Farber Cancer Institute Inc
University of Texas System
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2446806A1 publication Critical patent/CA2446806A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Oncology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Pulmonology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA002446806A 2001-05-11 2002-05-08 Anti-cd26 monoclonal antibodies as therapy for diseases associated with cells expressing cd26 Abandoned CA2446806A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US29053101P 2001-05-11 2001-05-11
US60/290,531 2001-05-11
PCT/US2002/014462 WO2002092127A1 (en) 2001-05-11 2002-05-08 Anti-cd26 monoclonal antibodies as therapy for diseases associated with cells expressing cd26

Publications (1)

Publication Number Publication Date
CA2446806A1 true CA2446806A1 (en) 2002-11-21

Family

ID=23116424

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002446806A Abandoned CA2446806A1 (en) 2001-05-11 2002-05-08 Anti-cd26 monoclonal antibodies as therapy for diseases associated with cells expressing cd26

Country Status (8)

Country Link
US (2) US7198788B2 (enExample)
EP (1) EP1392361A4 (enExample)
JP (1) JP2004533449A (enExample)
KR (1) KR100863624B1 (enExample)
CN (2) CN101172158A (enExample)
AU (1) AU2002308637B2 (enExample)
CA (1) CA2446806A1 (enExample)
WO (1) WO2002092127A1 (enExample)

Families Citing this family (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000018885A1 (en) * 1998-09-29 2000-04-06 Gamida Cell Ltd. Methods of controlling proliferation and differentiation of stem and progenitor cells
IL152904A0 (en) * 2002-01-24 2003-06-24 Gamida Cell Ltd Utilization of retinoid and vitamin d receptor antagonists for expansion of renewable stem cell populations
EP1465982A4 (en) * 2002-01-25 2006-06-07 Gamida Cell Ltd PROCESS FOR EXPANSION OF STEM AND PRESERVATIVE CELLS AND EXPANDED CELL POPULATIONS THEREWITH OBTAINED
EP1485464A4 (en) * 2002-03-18 2006-11-29 Gamida Cell Ltd METHODS OF INDUCING DIFFERENTIATION IN EX VIVO EXPANDED STEM CELLS
CA2497628A1 (en) * 2002-09-05 2004-03-18 Medimmune, Inc. Methods of preventing or treating cell malignancies by administering cd2 antagonists
US20050054097A1 (en) * 2002-11-17 2005-03-10 Tony Peled EX-VIVO expansion of hematopoietic system cell populations in mononuclear cell cultures
CA2508348C (en) * 2002-12-06 2016-07-12 Millennium Pharmaceuticals, Inc. Methods for the identification, assessment, and treatment of patients with proteasome inhibition therapy
US20040202666A1 (en) * 2003-01-24 2004-10-14 Immunomedics, Inc. Anti-cancer anthracycline drug-antibody conjugates
WO2004087053A2 (en) 2003-03-25 2004-10-14 Syrrx, Inc. Dipeptidyl peptidase inhibitors
MX369959B (es) 2003-05-14 2019-11-27 Immunogen Inc Composicion de farmaco conjugado.
EP1625122A1 (en) 2003-05-14 2006-02-15 Takeda San Diego, Inc. Dipeptidyl peptidase inhibitors
US7579357B2 (en) 2003-08-13 2009-08-25 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
WO2006030442A2 (en) * 2004-09-16 2006-03-23 Gamida-Cell Ltd. Methods of ex vivo progenitor and stem cell expansion by co-culture with mesenchymal cells
EP1853322B1 (en) 2005-02-11 2014-06-25 ImmunoGen, Inc. Process for preparing maytansinoid antibody conjugates
RU2486204C2 (ru) * 2005-07-22 2013-06-27 Уай'З Терапьютикс Ко., Лтд. Антитела против сd26 и способы их применения
NZ564843A (en) 2005-08-03 2012-05-25 Immunogen Inc Immunoconjugate formulations comprising an immunoconjugate and an excipient in a buffered aqueous solution
WO2007024536A2 (en) 2005-08-24 2007-03-01 Immunogen, Inc. Process for preparing maytansinoid antibody conjugates
EP1942898B2 (en) 2005-09-14 2014-05-14 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors for treating diabetes
CN101360723A (zh) 2005-09-16 2009-02-04 武田药品工业株式会社 制备嘧啶二酮衍生物的方法
US20090162405A1 (en) * 2006-12-14 2009-06-25 Yong Qian Proteinase-engineered cancer vaccine induces immune responses to prevent cancer and to systemically kill cancer cells
US8846393B2 (en) 2005-11-29 2014-09-30 Gamida-Cell Ltd. Methods of improving stem cell homing and engraftment
TW200838536A (en) 2006-11-29 2008-10-01 Takeda Pharmaceutical Polymorphs of succinate salt of 2-[6-(3-amino-piperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-ylmethy]-4-fluor-benzonitrile and methods of use therefor
KR101334934B1 (ko) * 2006-12-27 2013-11-29 삼성디스플레이 주식회사 유기발광표시장치의 에이징 방법
JP4865868B2 (ja) 2007-03-14 2012-02-01 国立大学法人 東京大学 悪性中皮種の治療方法
KR200450480Y1 (ko) * 2008-09-22 2010-10-07 대우조선해양 주식회사 앵글 취부장치
WO2010099918A1 (en) * 2009-03-06 2010-09-10 Klaus Tschira Stiftung Ggmbh Pharmaceutical composition and method for identifying a cancerous and/or an inflammatory disease in a patient
SG176068A1 (en) 2009-06-03 2011-12-29 Immunogen Inc Conjugation methods
US8321012B2 (en) * 2009-12-22 2012-11-27 The Invention Science Fund I, Llc Device, method, and system for neural modulation as vaccine adjuvant in a vertebrate subject
AU2011223883B2 (en) * 2010-03-01 2015-10-08 Cavion, Inc. Cancer diagnosis and imaging
EP2554552B1 (en) * 2010-03-26 2015-05-13 The University of Tokushima Novel anti-cd98 antibody and use thereof
CN103717262B (zh) 2011-03-29 2017-09-15 伊缪诺金公司 通过一步法制备类美登素抗体缀合物
CN104254778A (zh) * 2012-02-10 2014-12-31 西雅图遗传学公司 Cd30+癌症的检测和治疗
AU2013219945B2 (en) 2012-02-13 2017-12-07 Gamida-Cell Ltd. Culturing of mesenchymal stem cells
US9567569B2 (en) 2012-07-23 2017-02-14 Gamida Cell Ltd. Methods of culturing and expanding mesenchymal stem cells
US9175266B2 (en) 2012-07-23 2015-11-03 Gamida Cell Ltd. Enhancement of natural killer (NK) cell proliferation and activity
MX359599B (es) 2012-10-04 2018-09-12 Immunogen Inc Uso de una membrana de pvdf para purificar conjugados de agentes de unión celular y agentes citotóxicos.
EP2767549A1 (en) * 2013-02-19 2014-08-20 Adienne S.A. Anti-CD26 antibodies and uses thereof
US11242399B2 (en) 2013-02-19 2022-02-08 Adienne S.A. Anti-CD26 antibodies
CN105407723A (zh) 2013-03-15 2016-03-16 G1治疗公司 高效的抗赘生剂和抗增生剂
WO2014144847A2 (en) 2013-03-15 2014-09-18 G1 Therapeutics, Inc. Hspc-sparing treatments for rb-positive abnormal cellular proliferation
JP2015030666A (ja) 2013-07-31 2015-02-16 学校法人順天堂 抗ヒトｃｄ２６モノクローナル抗体又はその抗原結合性断片
CN103709251B (zh) * 2013-12-19 2016-04-13 江苏众红生物工程创药研究院有限公司 全人源抗cd26抗体及其应用
CN103694352B (zh) * 2013-12-19 2015-12-09 江苏众红生物工程创药研究院有限公司 一种抗 cd26 抗体及其制备方法
TWI677505B (zh) * 2014-08-18 2019-11-21 瑞士商艾迪安納股份有限公司 抗ｃｄ２６抗體及其用途
WO2016040858A1 (en) 2014-09-12 2016-03-17 G1 Therapeutics, Inc. Combinations and dosing regimes to treat rb-positive tumors
WO2016040848A1 (en) 2014-09-12 2016-03-17 G1 Therapeutics, Inc. Treatment of rb-negative tumors using topoisomerase inhibitors in combination with cyclin dependent kinase 4/6 inhibitors
KR20230144660A (ko) 2014-12-04 2023-10-16 셀진 코포레이션 생체분자 컨쥬게이트
EP3242686B1 (en) * 2015-01-09 2020-07-08 Medimmune, LLC Assay to detect human dpp-4
RU2020142534A (ru) * 2015-09-11 2021-02-01 И' с АК Ко., Лтд. Композиция для лечения рака, объединяющая анти-cd26 антитело и другое противораковое средство
PT3380525T (pt) 2015-11-25 2024-02-05 Immunogen Inc Formulações farmacêuticas e métodos que as utilizam
US11963980B2 (en) * 2016-04-25 2024-04-23 Musc Foundation For Research Development Activated CD26-high immune cells and CD26-negative immune cells and uses thereof
MA51309A (fr) * 2017-12-22 2021-03-31 Adienne S A Procédé cellulaire quantitatif pour déterminer l'activité biologique d'un ligand anti-cd26
CN109709337B (zh) * 2018-12-28 2021-09-14 江苏众红生物工程创药研究院有限公司 人cd26的免疫组化检测试剂盒及其临床应用
CN109535255B (zh) * 2018-12-28 2020-10-27 江苏众红生物工程创药研究院有限公司 一种抗人cd26抗体及其在检测试剂盒中的应用
EP3972606A4 (en) * 2019-05-20 2022-09-21 Mayo Foundation for Medical Education and Research TREATMENT OF CHRONIC LIVER DISEASE
CA3155930A1 (en) * 2019-09-27 2021-04-01 Starkage Therapeutics Senescent cell-associated antigen-binding domains, antibodies and chimeric antigen receptors comprising the same, and uses thereof
US11723926B2 (en) 2019-09-27 2023-08-15 Starkage Therapeutics Senescent cell-associated antigen-binding domains, antibodies and chimeric antigen receptors comprising the same, and uses thereof
US10988479B1 (en) 2020-06-15 2021-04-27 G1 Therapeutics, Inc. Morphic forms of trilaciclib and methods of manufacture thereof
WO2022220232A1 (ja) * 2021-04-12 2022-10-20 国立大学法人 東京大学 すい臓がん検出用蛍光プローブ
MX2023012633A (es) 2021-05-13 2023-11-09 Adienne S A Metodos de tratamiento de la enfermedad de injerto contra hospedero.
KR20240007230A (ko) 2021-05-13 2024-01-16 아디에네 에스.에이. 피부근염을 치료하는 방법
CN116023491A (zh) * 2021-10-25 2023-04-28 江苏众红生物工程创药研究院有限公司 抗cd26抗体及其应用
CN116549629A (zh) * 2022-01-30 2023-08-08 江苏众红生物工程创药研究院有限公司 Cd45作为生物标志物在筛查cd26抗体或其衍生物治疗肿瘤有效性和精准性中的应用
CN114878820A (zh) * 2022-05-30 2022-08-09 湛江中心人民医院 肺腺癌病理诊断标志物及其应用
WO2025027529A1 (en) 2023-07-31 2025-02-06 Advesya Anti-il-1rap antibody drug conjugates and methods of use thereof
CN117568477B (zh) * 2023-10-17 2024-11-19 中山大学肿瘤防治中心（中山大学附属肿瘤医院、中山大学肿瘤研究所） Dpp4作为nk/t细胞淋巴瘤肿瘤标志物的应用
TW202530255A (zh) 2023-12-15 2025-08-01 法商亞維西亞有限公司 抗ｉｌ－１ｒａｐ結合結構域及其抗體－藥物偶聯物

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5120642A (en) * 1989-11-28 1992-06-09 Coulter Corporation Monoclonal antibody which distinguishes helper inducer and suppressor inducer cd4+ lymphocytes
US5863904A (en) * 1995-09-26 1999-01-26 The University Of Michigan Methods for treating cancers and restenosis with P21
US6951924B2 (en) * 1997-03-14 2005-10-04 Human Genome Sciences, Inc. Antibodies against secreted protein HTEBYII
US6573096B1 (en) * 2000-04-01 2003-06-03 The Research Foundation At State University Of New York Compositions and methods for inhibition of cancer invasion and angiogenesis
WO2002004610A2 (en) * 2000-07-10 2002-01-17 Bayer Aktiengesellschaft Regulation of human dipeptidyl-peptidase iv-like enzyme
NZ525443A (en) * 2000-10-12 2006-04-28 Ferring Bv Dipeptidyl peptidase IV related genes

Also Published As

Publication number Publication date
AU2002308637B2 (en) 2007-05-17
CN1671415A (zh) 2005-09-21
EP1392361A1 (en) 2004-03-03
CN100341572C (zh) 2007-10-10
EP1392361A4 (en) 2009-08-05
WO2002092127A1 (en) 2002-11-21
US7658923B2 (en) 2010-02-09
US7198788B2 (en) 2007-04-03
JP2004533449A (ja) 2004-11-04
CN101172158A (zh) 2008-05-07
US20030031665A1 (en) 2003-02-13
US20070207143A1 (en) 2007-09-06
KR100863624B1 (ko) 2008-10-15
KR20040029984A (ko) 2004-04-08

Similar Documents

Publication Publication Date Title
AU2002308637B2 (en) Anti-cd26 monoclonal antibodies as therapy for diseases associated with cells expressing cd26
AU2002308637A1 (en) Anti-CD26 monoclonal antibodies as therapy for diseases associated with cells expressing CD26
ES2668874T3 (es) Anticuerpos anti-CEACAM1 y métodos de uso de los mismos
Li et al. Characterization of SGN-CD123A, a potent CD123-directed antibody–drug conjugate for acute myeloid leukemia
US8658168B2 (en) Compositions and methods for homoconjugates of antibodies which induce growth arrest of apoptosis of tumor cells
US7691376B2 (en) Ovarian cancer cell and myeloma cell surface glycoproteins, antibodies thereto, and uses thereof
US20040023870A1 (en) Methods of therapy and diagnosis using targeting of cells that express toll-like receptor proteins
US20050281813A1 (en) Methods of therapy and diagnosis using targeting of cells that express toll-like receptor proteins
CN106573976B (zh) 抗cd84抗体、包含所述抗体的组合物及其用途
IL188594A (en) Anti-ccr7 receptor antibodies for the treatment of cancer
WO2003047623A1 (en) Treatment of prostate cancer by inhibitors of ncam2
EP1350085A2 (en) Monoclonal antibodies and cell surface antigens for the detection and treatment of small cell lung cancer (sclc)
CN101622342B (zh) 减轻癌性疾病的抗体
JP2009536217A (ja) Ｂ細胞障害の治療における免疫グロブリン結合細胞表面決定基
JP2003520250A (ja) 一部の癌の治療における抗フェリチンモノクローナル抗体の使用
AU2007209787B2 (en) Anti-CD26 monoclonal antibodies as therapy for diseases associated with cells expressing CD26
US20040005317A1 (en) Methods of therapy and diagnosis using immunotargeting of CD84Hy1-expressing cells
HK1120415A (en) Anti-cd26 monoclonal antibodies as therapy for diseases associated with cells expressing cd26
US20040109863A1 (en) Methods of therapy and diagnosis using targeting of cells that express Ly-9
US7226750B1 (en) Ovarian cancer cell and myeloma cell surface glycoproteins, antibodies thereto, and uses thereof
US20040109862A1 (en) Methods of therapy and diagnosis using targeting of cells that express Ly-9

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued

Effective date: 20150424